Clinical Trials Logo

T-Cell Lymphoma clinical trials

View clinical trials related to T-Cell Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05442554 Active, not recruiting - T-Cell Lymphoma Clinical Trials

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Start date: July 20, 2023
Phase: Phase 4
Study type: Interventional

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.

NCT ID: NCT04712864 Active, not recruiting - T-Cell Lymphoma Clinical Trials

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL) (Sézary syndrome [SS] and mycosis fungoides [MF]).

NCT ID: NCT04502446 Active, not recruiting - T Cell Lymphoma Clinical Trials

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Start date: July 31, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.

NCT ID: NCT03952078 Active, not recruiting - T-cell Lymphoma Clinical Trials

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Start date: May 3, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.

NCT ID: NCT03792256 Active, not recruiting - Acute Leukemia Clinical Trials

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Start date: April 11, 2019
Phase: Phase 1
Study type: Interventional

AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are most commonly treated with ALL regimens. The proposed palbociclib starting dose for this study will be 50 mg/m^2/day for 21 days.

NCT ID: NCT01430013 Active, not recruiting - T Cell Lymphoma Clinical Trials

Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Start date: June 2011
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.

NCT ID: NCT01181271 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Tandem Auto-Allo Transplant for Lymphoma

Start date: August 2010
Phase: Phase 2
Study type: Interventional

Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.